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The functional role of oncogenes in human lung carcinogenesis has been investigated by transfer of
activated oncogenes into normal cells or an immortalized bronchial epithelial cell line, BEAS-2B. Trans-
fection ofv-Ha-ras, Ki-ras, or the combination of myc and rafinto BEAS-2B cells produced tumorigenic
cell lines, while transfection ofrafor mycaloneproduced nontumorigenic cell lines. In additionto studying
the pathogenic role of oncogenes, we are attempting to define negative growth-regulating genes that have
tumor-suppressive effects for human lung carcinomas. Our strategy to identify tumor-suppressor genes
involves loss of heterozygosity studies, monochromosome-cell fusion, and cell-cell fusion studies. Loss of
heterozygosity studies have revealed consistent allelic DNA sequence deletions on chromosome 17p in
squamouscell carcinomas, whilelargecell carcinomas andadenocarcinomas retainedthislocus. Mutations
in p53, a tumor-suppressor gene located on chromosome 17p, have been observed. Cell-cell hybrid clones
produced from fusion of nontumorigenic BEAS-2B cells with tumorigenic HuT292DM cells generally are
nontumorigenic. The mechanistic role of the known tumor-suppressor genes Rb-i and p53 in the devel-
opment ofhuman lungcarcinomas is beinginvestigated inthisepithelial cell model ofhumanbronchogenic
carcinogenesis.
Introduction
Carcinogenesis has long been thought to be due to an
accumulation of genetic and epigenetic changes that
cause abnormal regulation of molecular control of cell
growth. The genetic changes can be the activation of
proto-oncogenes and/or the inactivation of tumor-sup-
pressor genes that can initiate tumorigenesis as well as
enhance its progression. For example, Ki-ras activation
in colorectal carcinoma is considered an early event (1),
and gene amplification of N-myc has been associated
with progression of human neuroblastoma (2). To date,
only two tumor-suppressor genes have been well char-
acterized. The retinoblastoma gene, Rb-i, has been
found to be inactivated by mutation including deletions
in retinoblastomas and other human tumors (3-5). The
other tumor-suppressor gene recently identified is p53,
which is mutated in colorectal, breast, brain, and lung
carcinomas and may be involved in tumor progression
(6,7).
Oncogenes
Our strategy for investigating the role of oncogenes
in the neoplastic transformation ofnormal human bron-
chial epithelial cells is shown in Table 1. Seven families
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Table 1. Strategy for studying neoplastic transformation of
human bronchial epithelial cells by activated proto-oncogenes.
a) Select activated proto-oncogenes associated with human lung
cancer
b) Transfer activated proto-oncogenes into the progenitor epithelial
cells of bronchogenic carcinoma
c) Select preneoplastic and neoplastic cells from putative
suppressive normal cells
d) Determine tumorigenic potential in athymic nude mice
e) Investigate dysregulation in molecular controls of growth and
terminal differentiation
of activated proto-oncogenes, ras, raf, jun, erb-B2
(neu), fur, myb, and myc, have been associated with
human lung cancer. The functional role of these onco-
genes in lung carcinogenesis is being studied in vitro
by introducing these genes, singly or in combination,
into normal human bronchial epithelial cells (NHBE)
and SV40 T-antigen "immortalized" bronchial epithelial
cells. Since the NHBE cells are the presumed progen-
itorcellsforbronchogenic carcinoma, wehaveoptimized
theirgrowth in culture by creating a chemically defined
medium (8). This medium is free of serum and trans-
forming growth factor-1,3 (TGF-Pl), which will induce
terminal squamous differentiation in these cells (9).
To study the functional involvement of Ha-ras in hu-
man lung carcinoma, we have transfected v-Ha-ras into
NHBE cells (10). The transfected cells sustained pro-
gressive genotypic and phenotypic changes that in-LEHMAN ET AL.
eluded decreased responsiveness to induction of ter-
minal squamous differentiation, increased responsive-
ness to serum mitogens, increased life span, increased
chromosomal aberrations and, rarely, immortality and
tumorigenicity in athymic nude mice (Table 2). There-
fore, neoplastic transformation of NHBE cells by Ha-
ras is a rare event. Both the occurrence of frequent
chromosomal aberrations and the lengthy cell crisis pe-
riod ofthese transfected cells suggest that one or more
unidentified events, in addition to the introduction of
Ha-ras, may be involved in the development ofthe neo-
plastic phenotype.
Normal human cells in culture are relatively resistant
to neoplastic transformation events (11). Several stud-
ies have indicatedthatimmortalization is arate-limiting
step in the multistage process of in vitro human cell
carcinogenesis (12-14). In order to develop an immor-
talized cellsystemforstudies ofcarcinogenesis, wehave
infected NHBE cellswiththe SV40largeTantigengene
(15). Unlike the NHBE cells, these SV40 T-antigen-
containing cells, e.g., the BEAS-2B cell line, became
immortalized. An attractive feature of these cells for
use in carcinogenesis assays is the fact that they are
nontumorigenic inearlypassage. Inaddition, these cells
are aneuploid and undergo squamous differentiation in
response to serum or TGF-P1 (9). This is illustrated in
Figure 1.
Many human lung adenocarcinomas have been shown
to contain activated ras genes, which are thought to be
involved in both early and late stages ofcarcinogenesis
(1,16-20). The activated ras gene is most frequently Ki-
Table 2. Progressive phenotypic and genotypic changes in
normal human bronchial epithelial cells transfected with
v-Ha-ras.
Decreased response to inducers of terminal squamous
differentiation
Increased response to serum mitogens
Increased frequency of chromosomal aberrations and aneuploidy
Increased cell population doublings
Cell "crisis"
Continuous cell line
Tumorigenicity
Increased ras p21 expression in tumor cells
Metastasis
Normal
Properties
* Karotype Diploid
* Sensitivity to Normal
differentiation
inducers
* Anchorage Negative
independent
growth
* TumorigenicitY Negative
in athymic
nude mice
"Immortalized" Malignant
Aneuploid
Variable
Variable
Negative
FIGURE 1. Multistep human epithelial cell carcinogenesis in vitro.
Immortalization appears to be the rate-limiting step in in vitro
human cell carcinogenesis.
ras, but activated N-ras and Ha-ras have also been
observed in lung cancer cell lines (21). In this labora-
tory, the immortalized BEAS-2B cell line has beenused
to define conditions under which ras and other onco-
genes reproducibly cause neoplastic transformation.
Infection of BEAS-2B cells with a recombinant re-
trovirus containing v-Ha-ras produced cells (BZR) that
were tumorigenic in athymic nude mice (14). Tumor
analysis revealed cells of human origin with the isoen-
zyme phenotype and marker chromosomes ofBEAS-2B
cells. In addition, cell lines developed from the BZR
tumors (BZRT33 and others) expressed abundant 21-
kDa protein immunoreactive to antibodies specific for
the codon 12 mutation present in the v-Ha-ras protein
was autophosphorylated, indicating expression ofthe v-
Ha-ras gene as opposed to an endogenous ras gene.
BEAS-2B, BZR, and BZRT33 cells were also examined
for their invasiveness, metastatic potential, and ability
to repopulate de-epithelialized rat tracheal xenotran-
splants. Injection of these three cell lines into athymic
nude mice revealed that BEAS-2B were not tumori-
genic, BZR cells induced tumors with a latency period
of 1 to 3 weeks, and BZRT33 induced tumors in less
than 1 week (14). The incidence ofspontaneous metas-
tasis to the lung following subcutaneous injection was
negative for BEAS-2B (0%), intermediate for BZR
(33%), and extensive for BZRT33 (100%) (14).
Immortalized BEAS-2B cells were able to reconsti-
tute a mucous-producing columnar epithelium in de-ep-
ithelialized rat tracheas that were transplanted subcu-
taneously into athymic nude mice (22). BZR cells were
tumorigenic in this model system, and the tumor de-
rived cell lines, e.g., BZRT33 and BZRT35 cells, that
have increased ploidy and increased expression of the
v-Ha-ras p21 protein, were more malignant than the
BZR cells. This increasing malignancy in the tumor-
derived cell lines correlated with increased type IV col-
lagenase enzyme activity and mRNA expression (22).
The presence ofan activated c-Ki-ras gene in human
lung carcinomas has been well documented (20,23-27).
We have investigated the role ofKi-ras inthe multistep
neoplastic transformation ofhuman bronchial epithelial
cells. The v-Ki-ras oncogene used for these transfec-
tions contained mutations at codons 12 and 59. The mu-
tation at codon 12 has also been observed in the lung
carcinoma cell line A549 (28). Transfer ofthis oncogene
into BEAS-2B by either infection or transfection re-
sulted in neoplastic transformation (29). Tumors in-
duced by the transfection of v-Ki-ras had adenocarci-
nomatous elements (29). This is an interesting obser-
vation since the Ki-ras oncogene is most frequently
found to be activated in human lung cancers, and most
ofthese are adenocarcinomas.
Abnormalities in the raf, myc, and ras proto-onco-
gene families have been associated with both human
small cell (30-35) and nonsmall cell lung carcinomas
(20,36-38). We have assayed the functional role of c-
raf-1 and c-myc proto-oncogenes in lung carcinogenesis
by introducing these genes, both alone and in combi-
nation, into human bronchial epithelial BEAS-2B cells
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(39). Two retroviral recombinants, p-Zip-rafand p-Zip-
myc, containing the complete coding sequences of the
human c-raf-1 and the murine c-myc genes, respec-
tively, were constructed and transfected into BEAS-2B
cells. BEAS-2B cells transfected with Zip-raf or Zip-
myc alone were nontumorigenic after 12 months, but
BEAS-2B cells transfected with Zip-raf and Zip-myc
together formed large cell carcinomas in athymic nude
mice in 4 to 21 weeks (39). Carcinomas induced by the
combination of c-raf-1 and c-myc were of human epi-
thelial origin and exhibited specific surface antigens and
several neuroendocrine markers. An increase in the
mRNA levels of neuron-specific enolase was detected
in BEAS-2B cells containing c-raf-1 and c-myc genes,
suggesting an association between transformation and
the expression ofseveral neuroendocrine markers (Pfei-
fer et al., unpublished results).
Tumor Suppression
The primary indication for the existence ofthe dom-
inantly acting tumor-suppressor genes originates from
epidemiological studies (3). Further evidence comes
from the analysis of genetic loci exhibiting DNA re-
striction-fragment-length polymorphisms (RFLP)
showing reduction in homozygosity of chromosome 13
in retinoblastoma and osteosarcoma (5,40,41) and on
chromosome 11 in Wilms' tumor (42,43) and bladder
carcinoma (44). These latter studies have been corrob-
orated bygenetic studies usingthe technique ofsomatic
cell hybridization (45,46). Our strategy to identify tu-
mor-suppressor genes involved in human lung cancer
involves several approaches, which are illustrated in
Table 3.
Loss of Heterozygosity
Since the location of the tumor-suppressor genes is
unknown and since thesegenes mayhavedifferent func-
tions, a well-defined and comprehensive approach is re-
quired. Aninitialapproachisallelic DNAsequencedele-
tion analysis that identifies the chromosomal regions
that may harbor the tumor-suppressor genes. The loss
Table 3. Strategy for identifying and studying tumor-suppressor
genes in lung carcinogenesis.
a) Identify chromosomal location of putative tumor-suppressor
genes
i. Allelic deletion analysis of tumor DNA versus germ line DNA
ii. Monochromosome cell hybrids
b) Genetic analysis of somatic cell hybrids
c) Isolate genes by subtraction library approach
i. Tumorigenic versus nontumorigenic hybrids
ii. Terminal squamous differentiation-resistant versus
differentiation-sensitive cells
d) Isolate genes by insertional mutagenesis approach
e) Determine structure and function of isolated genes:
p53
Rb-i1
Nm23
Others
of heterozygosity (LOH) of RFLP has been used to
investigate the loss ofallelic DNA sequences on specific
chromosomes in several types of hereditary and spo-
radic tumors (40,42-44,47-51). RFLP analysis came
into prominence when the analysis ofloci on 13q in he-
reditary retinoblastoma revealed the loss of genes on
13q. This eventually led to the identification ofthe Rb-
1 gene on chromosome 13q. Recent RFLP analyses of
llp have detected loss ofalleles inWilms' tumor (47,48)
and also in tumors associated with Beckwith-Wiede-
mann syndrome (52).
Many RFLP studies of human lung cancer have fo-
cused on small cell carcinoma (53,54). A small number
ofnonsmall cell carcinomas have been studied by DNA
sequence deletion analysis (53-55). Recently, we have
concluded an extensive analysis of nonsmall cell lung
carcinoma for allelic DNA sequence losses on six dif-
ferent chromosomes at 13 different genetic loci. This
study was conducted on tumors of varied histological
types including squamous cell carcinoma, adenocarci-
noma of the lung, and large cell carcinoma ofthe lung.
This analysis allowed the comparison ofthe allelic DNA
sequence losses in different histological classes of tu-
mors (56). Interestingly, in squamous cell carcinoma,
consistent LOH was found at 17pi3 using the D17S1
probe, while consistent LOH at this locus in adenocar-
cinomas and large cell carcinomas was not detected.
Frequent LOH at this locus has also been associated
with colorectal (57-59) and small cell carcinoma of the
lung (53,55,60,61).
LOH on chromosome 3 has been reported in small
cell carcinomas (53-55,60-62). It has been speculated
that this region contains a putative tumor-suppressor
geneforsmallcellcarcinomas ofthelung(53). Ourstudy
ofLOH for markers on chromosome 3 in approximately
60% ofthe tumorsshowedagreementwithotherreports
that use DNA-RFLP to examine genetic loci on chro-
mosome 3 in nonsmall cell lung carcinoma. However,
LOH is substantially less than 100%, which is not in
agreement with one report (62) in the literature.
We have studied chromosome 11 extensively for loss
ofalleles because it has been speculated to have at least
one if not more tumor-suppressor genes. Six different
loci on this chromosome have been studied. LOH was-
observed in 45% of the squamous cell carcinomas and
adenocarcinomas studied (56). LOH was most fre-
quently observed at the HBG2, insulin, and c-Ha-ras
loci in both types of cancers. From these data, it was
possible to establish two commonly deleted regions in
lung cancer for this chromosome, namely, llpter-p15.5
and 11p13-11q13 (Fig. 2). These findings are consistent
with observations that describe two separate regions
on chromosome 11 that may harbor tumor-suppressor
genes that correspond to llpl3 in Wilms' tumor and
llpter-11p15.5 in rhabdomyosarcoma (42,63).
The LOH results obtained for nonsmall cell lung car-
cinoma show differences in the genetic deletions ob-
served in various histological types oflung cancers; mi-
totic recombination was a rare cause of LOH. Inter-
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FIGURE 2. Schematic representation of shortest region of overlapping DNA sequence deletion analysis on chromosome 11 for nine squamous
cell carcinomas (squamous), seven adenocarcinomas (adeno), and three large cell carcinomas (large) of the lung. Solid lines show intact
genetic loci, dashed lines show regions for which no information is available, and gaps show regions of gene deletion.
estingly, in squamous cell carcinoma, coincidental LOH
for several chromosomes was observed. For example,
in eight of nine cases, allelic DNA.-sequence deletion
was observed for both chromosomes 11 'and 17 where
the analyses were informative for both chromosomes.
Similarly, allelic DNA sequence deletions occurred for
chromosomes 3 and 17 in 3 of5 informative cases. Other
combinations of coincident loss in squamous and aden-
ocarcinomas of the lung are shown in Figure 3.
The genetic changes observed in these tumors may
also be involved in the pathogenesis of lung cancer in
combination with other tumor-suppressor genes. From
this study, we can conclude that loss ofputative tumor-
suppressor genes identified in other cancers may have
a role independently or in combination in the develop-
ment of nonsmall cell carcinoma.
Monochromosome-Cell Fusion
In several cases where LOH studies suggest that
deletion ofaparticular chromosomal regionisassociated
with development of tumorigenicity, the technique of
monochrornosome fusion (64,65) can be employed to in-
vestigate this hypothesis. Using this technique, a sin-
gle, normal human chromosome is introduced into re-
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FIGURE 3. Coincident loss of heterozygosity for numbered chro-
mosomes. For each of either 23 squamous cell or 23 adenocarci-
nomas of the lung, coincident loss of heterozygosity is shown for
different combinations ofchromosomes 3, 11, 13, and 17. Numbers
in bars indicate number of cases informative for the chromosome
indicated.
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cipient tumorigenic cells. The tumorigenic potential of
the microcell hybrid is assessed in athymic nude mice
andin manycases, suppressionofthetumorigenic phen-
otype is observed. For example, Stanbridge and co-
workers have shown that introduction of a normal hu-
man chromosome 11 into Wilms' tumor cells suppresses
tumorigenicity of these cells (66). Likewise, Oshimura
and co-workers have observed similar suppression in
cervical carcinoma cell lines (67,68), as has Stanbridge
et al., using HeLa cells (69). In addition, rhabdomy-
osarcoma cells, which are associated with lipi5 se-
quence deletions, were suppressed by the monochro-
mosome transfer of a normal human chromosome 11
(68). Therefore, the malignant growth of these three
different types of tumor cells appear to be dependent
on the absence of a gene or genes normally present on
chromosome 11.
Tumor suppression has also been documented for
other human chromosomes and malignant cells. Chro-
mosome 3 has been shown to revert tumorigenicity in
renal cells in which RFLP analysis has suggested that
3p deletions may be important in the development of
the disease (68).
Mostrecently, Nagle and co-workershave introduced
a normal human chromosome 6 into two human malig-
nant melanoma cell lines (70). In addition to reversion
of the transformed in vitro phenotype and decreased
soft-agarcloningefficiency, tumorigenicity ofthehybrid
cells was initially suppressed. Interestingly, all animals
later developed tumors. However, cytogenetic and
RFLP analysis of the tumors revealed a loss of the
introduced chromosome 6 from the melanoma cell hy-
brids (70).
Guided by our own LOH studies of human lung tu-
mors and lung tumor cell lines, we are currently intro-
ducing human chromosomes 3, 11, 13, and 17 into lung
cancer cell lines which are known to have sustained
deletions of allelic sequences in these chromosomal re-
gions. In addition, we are also sequentially introducing
several normal chromosomes into cells that have shown
multiple LOH from several different chromosomes. By
taking this approach, we expect to determine if loss of
one or more tumor-suppressor genes from different
chromosomes may be acting in cooperation for the de-
velopment of human lung carcinoma.
Cell-Cell Hybrids
Tumor suppression was first demonstrated by Harris
and co-workers, who produced murine cell hybrids be-
tween cells of high and low tumorigenic potential (71).
The tumorigenicity of these hybrids was transiently
suppressed, but as the hybrid clones were propagated
in culture, tumorigenic segregants rapidly developed.
As chromosomes in the hybrid cells were lost, the tu-
morigenicity ofthe hybrids increased to that ofthe par-
ent cell of high tumorigenic potential-(72).
Genetic analysis of somatic cell hybrids between tu-
morigenic and normal human cells has shown that sup-
pressor activity of the normal cell is functionally dom-
inant over the tumorigenic cell. Hybrids formed from
the human cervical carcinoma cell line, HeLa, and nor-
mal human fibroblasts (73) or normal human epidermal
keratinocytes (74) showed suppressed tumorigenicity,
as did hybrids between EJ bladder carcinoma cells con-
tainingamutantc-Ha-ras andnormalhumanfibroblasts
(75). However, studies that examine the tumorigenicity
of a cancerous cell type hybridized with its normal ep-
ithelial progenitor cell have not been performed. We
therefore created cell-cell hybrids between the cancer
cell line HuT292DM and NHBE, SV40 T-antigen "im-
mortalized" nontumorigenic human bronchus cells
(BEAS-2B) (15), or a weakly tumorigenic cell line de-
rived from BEAS-2B which has a 3p deletion (B39TL)
following growth in nude mice (Reddel et al., unpub-
lished observations). Hybrids formed between NHBE
and HuT292DM cells had a limited doubling potential
in culture and senesced after 40 to 43 population dou-
blings. Therefore, tumorigenicity assays could not be
performed withthesehybrids duetoinsufficientnumber
of cells.
In contrast to NHBE and HuT292DM cell hybrids,
hybrids of BEAS-2B and HuT292DM cells have an in-
definite lifespan in culture (76). Tumor incidence in the
parental line HuT292DM was 100% with amean latency
of 27 days, 50% in B39TL with a mean latency of 148
days, and 0% in BEAS-2B after approximately 1 year.
Hybrids ofBEAS-2B and HuT292DM cells yielded total
suppression of tumorigenicity in 76% of the mice in-
jected, while the immortalized, weakly tumorigenic
B39TL as a parent yielded only 54% suppression oftu-
morigenicity of HuT292DM. Tumorigenicity of the
B39TL x HuT292DM cell hybrids is comparable to the
tumorigenicity of the parent B39TL at 50% (7/14). In
addition, latency oftumor development in BEAS-2B x
HuT292DM cell hybrids was extended 2- to 3-fold over
thatoftheparent HuT292DM. Thesedataarepresented
in Table 4.
Cell lines were isolated from tumors arising from the
BEAS-2B x HuT292DM cell hybrids and the B39TL
x HuT292DM hybrids. Upon reinjection ofthese lines
into athymic nude mice, tumors were produced with
latency periods comparable to the parent HuT292DM
cells. These data suggest that reversion to tumor-form-
ing ability may occur due to loss of a chromosome(s)
that harbors a tumor-suppressor gene(s).
Karyotype analysis ofparental lines, cell-cellhybrids,
and hybrid-derived tumor cell lines was performed, and
the results are shown in Table 5. The parental lines are
hypodiploid, while the hybrid lines are hypotriploid to
hypotetraploid. The hybrid lines contained all the
marker chromosomes ofboth parents. In addition, new
markerchromosomes werepresentinthe hybridtumor-
derived cell lines as well as a loss ofthe Y chromosome
from B39TL in the B39TL x HuT292DM hybrid tumor
cell line. Karyotype analysis of the hybrid tumor cell
lines revealed varied chromosome counts, mostly in the
triploid range, suggesting a loss of chromosomes from
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Table 4. Suppression of tumorigenicity in somatic cell hybrids between a lung cancer cell line and immortalized bronchial
epithelial cells.
No. of injected Tumors/no. Latency, % Totally
Cell line mice of injected micea (days) %b suppressed No. regressedc
BEAS-2B 15 0/12 > 294 100 0
B39TL 15 7/14 148 50 3
HuT292DM 20 19/19 27 0 0
BEAS-2B x HuT292DMd 55 13/54 88e 76 1
B39TL x HuT292DMf 30 13/28 839 54 3
'A nonregressing nodule 3 1.0 cm in the largest dimension. Mice surviving less than 3 months without tumors have been excluded.
bMean number of days to reach scorable size.
cNot scored as tumors.
dPooled data from 11 hybrid lines each injected into mice.
eMean tumor latency in the remaining 24% of the hybrids that produced tumors.
'Pooled data from six hybrid lines each injected into five mice.
gMean tumor latency in the remaining 46% of the hybrids that produced tumors.
Table 5. Chromosomal characteristics of hybrids and parental lines.
Marker chromosomes
HuT292 BEAS- B39
Cell line Ploidy' DM 2B TL New Y-chromosome
Hybrids
HuT292DM x BEAS-2B-1, P14 75-85 (92)b 13 9 6 Present
HuT292DM x BEAS-2B-2, PlO 75-90 (95) 13 8 Present
HuT292DM x B39TL-1, P12 80-90 (94) 12 8 3 Present
HuT292DM x B39TL-2, PlO 75-90 (98) 15 7 3 Present
Tumor lines
HuT292DM x B39TL-T, P4 65-85 (93) 7 9 10 Absent
HuT292DM x BEAS-2B-T, P4 68-78 (92) 7 2 5 Present
Parental lines
HuT292DM 43-45 (96) 7 Absent
BEAS-2B, P27 44-48 (85) 6 Present
B39TL, P3 40-47 (90) 4 7 Present
aRange of chromosome numbers (% in range) based on counts of 100 metaphases/cell line.
'The remaining metaphases have 120 to 150 chromosomes.
the hypotriploid tohypotetraploid rangeobservedinthe
hybrids.
From these experiments, we can conclude that non-
tumorigenic orweakly tumorigenic parents in a cell-cell
hybrid with tumorigenic cells will dominantly control
culture longevity and tumorigenicity of the more tu-
morigenic parent. Further, genes other than those in-
volved in senescence can exhibit tumor suppressor
activity.
Retinoblastoma
Retinoblastoma is a childhood cancer that occurs in
familial and spontaneous forms. In 1971, Knudson pro-
posed that this retinal cancer is caused by two muta-
tional events (41). In the familial form, a germ-line mu-
tation predisposes the individual toretinoblastoma, and
a second mutation is acquired somatically, leading to
tumor development (41). In the spontaneous form of
retinoblastoma, both mutations are somatic in origin.
Further, those with the hereditary form are at risk for
developingsecondary cancers laterin life. These second
cancers are ofunusual types such as osteosarcoma and
fibrosarcoma. Individuals with the nonhereditary form
are at no increased risk for other cancers. The evidence
that one of these mutations creates an inactive allele
was provided by the loss of genetic material on chro-
mosome 13q14 in retinoblastomas (77). This also sug-
gestedthatthisregionharbors agene,Rb-i, thatserves
as the first target for inactivation by these mutations.
The second ofKnudson's hypothesizedtargetgenes was
soon identified to be the other copy of the intact Rb-i
gene. This was recognized by studying a closely linked
markergene, esterase D, onchromosome 13. LOHstud-
ies revealed that the esterase D gene was heterozygous
in normal tissue ofa retinoblastoma patient, but in the
tumorcells, it was reduced to a homozygous state. This
implied that in tumor cells, the intact Rb-i gene was
replaced by a copy of the mutated allele. This demon-
strated that both copies of the Rb-i gene need to be
lost orinactivated fortumordevelopment. UsingRFLP
techniques and chromosome walking, a candidate gene
for Rb-1 has been isolated and cloned (5,78,78). It has
been further shown that the Rb-1 protein is present in
normal retinoblasts but absent in retinoblastomas.
All ofthe evidence collected to date suggests thatthe
Rb-1 protein acts as a negative regulator of cell prolif-
eration (80-82). If this is true, the Rb-1 protein must
138ONCOGENES AND TUMOR-SUPPRESSOR GENES
be posttranslationally regulated. It has recently been
shown that the phosphorylation level of Rb-1 changes
rapidly, suggesting that specific kinases and phospha-
tases are involved. In addition, phosphorylation of Rb-
1 is linked to the cell cycle (83-86). Although synthesis
of the Rb-1 protein is relatively constant throughout
the cell cycle, phosphorylated Rb-1 protein can be de-
tected in cells in late G1 and S phase, while cells in Go
and early G1 are less phosphorylated. The state ofphos-
phorylation of the Rb-1 protein may act as a "gate" to
allow cells to enter S phase and proliferate. In contrast,
unphosphorylated Rb-1 protein may inhibit cell prolif-
eration and enhance differentiation.
Further evidence that the unphosphorylated form of
Rb-1 protein inhibits cell proliferation comes from work
by Ludlow (87) who demonstrated that SV40 T antigen
binds only to the unphosphorylated form of the Rb-1
protein. This binding may functionally inactivate the
unphosphorylated form of Rb-1 by removing its regu-
latory effects on the cell cycle and promoting cell pro-
liferation. The functional inactivation of Rb-1 by SV40
T-binding may correspond to the "second hit" of Knud-
son's hypothesis, thereby increasing the neoplastic po-
tential ofthese infected cells. This regulation may be a
key step in modulation of cell growth mediated by the
Rb-1 protein.
Several studies have shown that nuclear viral onco-
gene products from adenovirus ElA (88,89), SV40 T-
antigen (87,90) (as discussed above), and HPV16 E7
(91,92) bind to the Rb-1 protein. The importance of
these interactions has not been conclusively demon-
strated thus far. However, mutations in the Rb-1 bind-
ing regions of the viral protein ElA (89) and SV40 T-
antigen (90) prevent the association of viral oncogene
and Rb-i gene products. This has been hypothesized to
prevent entry ofthe virus-infected cells into S-phase of
the cell cycle, thus preventing viral DNA replication.
When viral DNAreplicationisprevented, theoncogenic
effects ofthe virus are not expressed, and Rb-i acts as
a suppressor of cellular transformation.
Several different abnormalities have been observed
in the Rb-i gene and its product in retinoblastoma, os-
teosarcoma, small cell lung carcinomas (SCLC), breast
and bladder carcinomas. These abnormalities include
point mutations altering splicing patterns of mRNA,
small deletions or duplications, truncations of the pro-
tein, and abnormal levels oftheRb-i transcript. In 50%
ofhumanretinoblastomatumors, pointmutations which
either alter the splicing pattern or generate small dele-
tions or duplications in the gene were observed (93,94).
Inactivation ofthe Rb-i gene may be involved in the
development of lung cancers as well, especially in the
case of SCLC. In 60% of SCLC studied, no detectable
Rb-1 transcript was observed, while 10% of the non-
SCLC had abnormal or absentRb-i transcripts (34,95).
All SCLC examined for Rb-1 protein were found to be
negative (95). One of four pulmonary carcinoids exam-
ined hadRb-i structural abnormalities, while three ex-
pressed no Rb-i mRNA (34).
Ourapproachhasbeentoexaminevariouslungcancer
and mesothelial cell lines for Rb-i abnormalities by
Northern blot analysis and by immunoprecipitation.
This will allow identification ofcell lines with defective
Rb-i genes forfurther characterization ofRb-i involve-
mentinlungcancerandmesotheliomas. Oncetheselines
have been identified, the Rb-i gene can be introduced
by DNA transfection or by microcell fusion with a cell
line containing a marked normal human chromosome 13
to determine biological effects oftheRb-i gene in these
cells.
One recent demonstration of tumor suppression by
Rb-i was shown by introducing the Rb-i gene into a
tumorigenic cell line which lacks the gene and then ex-
amining changes in growth and tumorigenic potential.
Lee and co-workers (82) have shown that introduction
of the cDNA from Rb-i into a retinoblastoma cell line
that lacks the Rb-1 protein as well as an osteogenic
sarcoma line expressing a truncated Rb-1 protein
greatly inhibited growth in culture and the ability to
grow in an anchorage-independent manner. Further-
more, the tumorigenic potential of the retinoblastoma
and osteogenic sarcoma cell lines was lost in the cells
which now contained the Rb-i gene (82). However, in-
troduction of the same Rb-i gene construct into the
human prostate cell line DU145, which has a 35 amino
acid in-frame deletion, did not significantly alter its ge-
netic growth rate in culture (96). Unlike the retinob-
lastoma and osteosarcomacelllinescontainingRb-1, the
tumorigenicity was not lost, but the tumor sizes were
greatly reduced in the mice injected with the prostate
cell line containing the Rb-i gene (96).
p53
Phosphoprotein p53 is a nuclear protein that is pres-
ent in high amounts in transformed human (97) and
mouse cells (98). Although no specific function has been
assigned to this protein, antibody injections into divid-
ingcells haveimplicated p53incellcycleregulation (99).
Initialstudies inratembryofibroblasts have shownthat
p53 can cooperate with ras in neoplastic transformation
(100). Recently, it has been shown that the p53 gene
used in this and other studies was mutated, and not the
wild type gene (101). In fact, it has been recently dem-
onstrated that wild-type p53 does not cooperate with
ras, but suppresses focus formation when co-trans-
fected with ras in this assay (102,103).
One of the best-characterized features of p53 is its
ability to form complexes with other proteins. p53 was
first identified in a complex with SV40 T-antigen
(98,104). Since that time, it has been found associated
with adenovirus Elb in transformed rodent cells (105)
and HPV16 E6 (P. Howley, personal communication).
In addition, p53 complexes with itself to form homo-
oligomeric struetures (106).
In situ hybridization analysis has assigned the p53
genetothe short armofhumanchromosome 17, banding
region 13 (107). As discussed above, several recent
RFLP studies in human lung carcinoma, breast carci-
noma, colorectal carcinoma, and brain tumors have
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shown LOH in this region ofthe chromosome. Thisfind-
ing led to the hypothesis that this region harbors a
tumor-suppressor gene. In a recent study, Vogelstein
and co-workers have shown that in two colorectal car-
cinomas, one ofthe 17p alleles is lost and the p53 gene
on the other is mutated, while normal tissue surround-
ing the tumor has the p53 wild-type sequence (6). This
finding has sparked speculation that progression of
thesetumors occursthrough adominant, negative effect
mediated by the presence of mutant p53 or complete
loss of wild-type p53 (6,102,108). A dominant negative
effect may occur when pseudohomodimers ofwild-type
and mutated p53 are formed which functionally inacti-
vate the wild type p53 (109).
To further explore the possible dominant negative
effect of mutant p53, Bernstein et al. (110) have gen-
erated independent lines of transgenic mice carrying
genomic clones of a mutant p53 gene. These mice ex-
pressed high levels of mutant p53 in a wide variety of
tissues and have a greatly elevated predisposition to
malignancies, particularly osteosarcomas, lung adeno-
carcinomas, and lymphomas (110). Both alleles of the
p53 gene used to develop the transgenic mice have sus-
tained mutation in the coding region. The elevated tu-
mor incidence in mice could be due to a dominant neg-
ative effect of functionally inactive transgenic protein
inhibiting normal endogenous wild-type p53 protein.
Previous studies in rodent systems have shown that
mutant p53 binds to cellular heat shock protein 70
(hsp70) (109). Immunoprecipitation using hsp antisera
orp53 antibodies has clearly demonstrated this complex
formation, which results from conformational changes
in the p53 due to mutation. The association ofp53 with
hsp70 in a human system has recently been demon-
strated (111). Cell lysates of a human osteosarcoma cell
line, HOS-SL, were immunoprecipitated with anti-
hsp70 and anti-p53 antibodies, and co-immunoprecipi-
tation ofp53 and hsp70 was observed. Subsequent clon-
ing and sequencing ofthe p53 gene has revealed a mu-
tation in codon 156 of the p53 gene (112). We are
currently using co-immunoprecipitation with hsp70 as
a rapid method of screening cell lines for mutations in
the p53 gene.
In the last year, there have been several reports re-
garding p53 mutations detected in human tumors and
cell lines (6,7,113). A wide range ofabnormalities ofthe
p53 gene, its RNA, and protein products have been
reported in human lung cancer cell lines. A panel of
human SCLC and non-SCLC cell lines have been ex-
amined as well as samples from normal lung obtained
at the time ofsurgical resection. Ofthe 30 lungcell lines
examined, one had a DNA rearrangement, 4 had ab-
normally sized p53 mRNA, 4 had decreased levels of
p53 mRNA, 2 had only trace amounts of p53 mRNA,
and 10 had point mutations (113).
Using the LOH studies on chromosome 17 as back-
ground, 21 tumors of various histological types (colo-
rectal, lung, breast, and brain) have been analyzed for
mutations in the p53 gene (7). Fifteen of the tumors
contained a single missense mutation, two contained
two missense mutations, one tumor had a frame-shift
mutation, and in three tumors, no p53 mutations were
detected. The mutations identified in this study were
clustered in four regions, hot spots of the p53 gene.
These regions, exons 5, 6, and 7, are the most highly
conserved among species (114). Although more dataare
needed, these initial results suggest that these regions
ofthep53genemaybeespeciallyimportantinmediation
ofthe normal function ofthe p53 gene product. Normal
cells from tissue surrounding these tumors were also
analyzed for p53 mutations, and none were found.
Wild-type p53 as a putative tumor-suppressor gene
has many properties in common with Rb-i, the only
other known tumor-suppressor gene. A comparison of
the characteristics and activities of the Rb-i and p53
gene products is shown in Table 6. Both these genes
encode nuclear phosphoproteins that bind DNA and
have a possible regulatory function in the cell cycle.
Most notably, both of these proteins form complexes
with oncoproteins of DNA tumor viruses. The binding
regions ofthese oncoproteins toRb-i and p53 are shown
in Figure 4. As was discussed earlier in the case ofRb-
1, these nuclear oncoproteins participate in transfor-
mation through at least one common mechanism,
namely, binding to and thereby inactivating Rb-i and/
or p53. Since p53 is believed to be involved in transition
of cells from G1 to the S-phase of the cell cycle, by
binding to the p53 protein, SV40 T-antigen would in-
activate this function of p53 in the cell cycle, promote
the replication ofviral DNA and cause transformation.
We are examining the status of p53 in primary lung
tumors compared to surrounding normal tissue and in
lung carcinoma cell lines. Several different approaches
are being taken. In the first approach, we are sequenc-
ing exons 5, 6, and 7 using intron primers to amplify
the DNA. The polymerase chain reaction product is
sequenced and examined for mutations.
The second approach takes advantage of the associ-
ation ofmutated p53 and heat shock proteins (115). Us-
ingantibodies againstboth p53 and heat shockproteins,
immunoprecipitations of the various cell lines are per-
formed, and the presence ofmutated p53 is detected by
the co-immunoprecipitation ofthe p53-hsp complex. As
lung cancer cell lines which contain a mutated p53 are
identified, they are then transfected with a variety of
plasmids containing wild-type p53 either constitutively
or inducibly expressed. In addition, NHBE and T-an-
tigen-immortalized BEAS-2B cells are also transfected
Table 6. Comparison of characteristics, activities, and functions
of Rb-i and p53 proteins.
Rb-i p53
DNA binding activity DNA binding activity
Nuclear phosphoprotein Nuclear phosphoprotein
Binds SV40 T-antigen Binds SV40 T-antigen
Binds adenovirus Ela Binds adenovirus Elb
Binds HPV-16 E7 Binds HPV-16 E6
Regulates transcription of Regulates G1-S transition in
cellular genes involved in normal cells
growth control
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* SV40
1 105 114 272 517 708
Large T Antigen
* Adenovirus Type 5
1 3059120127 243 1 496
ElA E1B
* Human Papilloma virus
E6 E7
* Heat Shock Protein 70
HSP-70
FIGURE 4. Schematic representation ofthe interaction between the
Rb-1 protein, p53, viral proteins, and heat shock protein 70.
with wild-type and mutated p53 in constitutive or in-
ducible expression vectors. The tumorigenicity ofthese
transfected cells, as well as growth characteristics, will
be determined. These experiments are designed to pro-
vide data that may give us some insight into the bio-
logicaleffectsofmutated andwild-typep53inlungcells.
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